Canaccord Genuity Initiates Coverage On Twist Bioscience with Buy Rating, Announces Price Target of $90

Benzinga Newsdesk www.benzinga.com Neutral 60.0%

Neg 0% Neu 60% Pos 0%

Canaccord Genuity analyst Kyle Mikson initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Buy rating and announces Price Target of $90.